1. Home
  2. PSN vs BLTE Comparison

PSN vs BLTE Comparison

Compare PSN & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Parsons Corporation

PSN

Parsons Corporation

HOLD

Current Price

$49.61

Market Cap

6.0B

Sector

Technology

ML Signal

HOLD

Logo Belite Bio Inc

BLTE

Belite Bio Inc

N/A

Current Price

$154.15

Market Cap

6.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PSN
BLTE
Founded
1944
2018
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.0B
6.6B
IPO Year
2019
2021

Fundamental Metrics

Financial Performance
Metric
PSN
BLTE
Price
$49.61
$154.15
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
13
7
Target Price
$79.18
$198.00
AVG Volume (30 Days)
1.1M
104.3K
Earning Date
04-29-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
3.77
N/A
EPS
0.49
N/A
Revenue
$6,364,245,000.00
N/A
Revenue This Year
$5.87
N/A
Revenue Next Year
$7.61
$492.11
P/E Ratio
$102.20
N/A
Revenue Growth
N/A
N/A
52 Week Low
$49.38
$56.68
52 Week High
$89.50
$200.00

Technical Indicators

Market Signals
Indicator
PSN
BLTE
Relative Strength Index (RSI) 32.74 40.61
Support Level $49.38 $148.06
Resistance Level $66.57 $161.28
Average True Range (ATR) 2.27 6.20
MACD -0.30 -1.18
Stochastic Oscillator 3.95 3.36

Price Performance

Historical Comparison
PSN
BLTE

About PSN Parsons Corporation

Parsons Corp is a provider of technology-driven solutions in the defense, intelligence, and critical infrastructure markets. The business activities of the group are carried out through Federal Solutions and Critical Infrastructure segments. The Federal Solutions segment is a high-end service and technology provider to the U.S. government, delivering timely, cost-effective solutions for mission-critical projects, whereas the Critical Infrastructure segment provides integrated design and engineering services for complex physical and digital infrastructure around the globe. The company derives maximum revenue from Federal Solutions segment. Geographically, the company derives revenue from North America; Middle East; and Rest of the World, of which North America derives maximum revenue.

About BLTE Belite Bio Inc

Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.

Share on Social Networks: